May 13, 2025

MEDIPAL HOLDINGS CORPORATION
Representative: Shuichi Watanabe, Representative Director, President and CEO
Code number: 7459 (Prime Market, Tokyo Stock Exchange)
Contact: Yuji Sakon,
Managing Director, General Manager of Administration Division
Tel: +81-3-3517-5171

Notice Regarding Decision on Matters Concerning Acquisition of Treasury Stock and Cancellation of Treasury Stock

At a meeting of the Board of Directors held on May 13, 2025, MEDIPAL HOLDINGS CORPORATION ("MEDIPAL") resolved matters related to the acquisition of treasury stock pursuant to Article 459, Paragraph 1 of the Companies Act and the MEDIPAL's Articles of Incorporation. And MEDIPAL resolved to cancel the treasury stock to be acquired through this resolution pursuant to Article 178 of the Companies Act. Details follow below.

1. Reasons for the acquisition and the cancellation of treasury stock

To improve capital efficiency through shareholder returns.

2. Details of the matters concerning the acquisition

(1)	Class of stock to be acquired	Common stock
(2)	Total number of shares to be acquired	Up to 4,000,000 shares (1.9% of the total number of common stock issued (excluding treasury stock))
(3)	Total acquisition cost	Up to 8 billion yen
(4)	Period of acquisition	From May 14, 2025 to October 31, 2025
(5)	Method of acquisition	Market buying on the Tokyo Stock Exchange

3. Details of the matters concerning the cancellation

(1)	Class of stock to be cancelled	Common stock
(2)	Total number of shares to be cancelled	The number corresponding to all of the treasury stock acquired through 2 above
(3)	Cancellation date	Implemented by December 31, 2025 after completion of the treasury stock acquired through 2 above

Reference

Status of treasury stock holding (as of April 30, 2025)

Total number of shares outstanding (excluding treasury stock)	207,950,180 Shares
Total number of treasury shares	11,275,862 Shares

# # #

The English version of this document is a translation of the Japanese original and is provided for information purposes only. While reasonable efforts have been made to provide an accurate translation, no liability is assumed by MEDIPAL HOLDINGS CORPORATION for any errors, omissions, or ambiguities in the translation. In the event of any inconsistency or conflict between the English version and the Japanese original, the Japanese original shall prevail.